1. Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
- Author
-
Jung-Ick Byun, Jun-Sang Sunwoo, Kyung Wook Kang, Keun Tae Kim, Daeyoung Kim, Dong Wook Kim, Saeyoon Kim, Se Hee Kim, Woojun Kim, Hye-Jin Moon, Hea Ree Park, Jong-Geun Seo, Min Kyung Chu, Kyoung Jin Hwang, and Dae-Won Seo
- Abstract
Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid®). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy.
- Published
- 2022